Multiple myeloma genomics now spans inherited risk, founding lesions, and relapse biology
Multiple myeloma is no longer best viewed as a single genomic disease with one dominant origin story. Its biology is better described as an evolving system in which inherited susceptibility, early oncogenic lesions, and therapy-driven selection pressures interact across time. The framework presented here organizes that progression into a sequence that begins before malignant plasma cells are clinically apparent and continues through relapse, clonal replacement, and resistance.
One sentence captures the practical shift: myeloma does not simply accumulate mutations; it evolves under pressure.
The model places germline predisposition at the starting point. Polygenic risk burden, rare predisposing variants, and disruption of DNA repair and telomere maintenance pathways can create a permissive background that shapes precursor states and immune interactions. Those inherited features do not define disease on their own, but they help determine which cellular contexts are more vulnerable to malignant transformation. In that sense, inherited risk is not a passive backdrop; it helps set the threshold for clonal emergence.
Germline susceptibility sets the stage before overt malignancy appears
The review distinguishes between broad inherited burden and clinically interpretable actionability. Polygenic risk scores can provide insight into inherited susceptibility, yet they are not ready for routine clinical use in screening or risk stratification in multiple myeloma. They remain research tools rather than bedside instruments.
Rare predisposing variants and pathway-level vulnerability may prove more informative than any single common variant. DNA repair defects and telomere pathway alterations are especially relevant because both can increase genomic instability over time. When repair capacity is weakened, early precursor clones may persist longer, diversify more easily, and acquire additional lesions under less biological restraint. Telomere dysfunction can also favor chromosomal instability, creating conditions in which structural abnormalities become more likely during disease evolution.
Founding cytogenetic events define the disease’s first major branch point
The first somatic steps matter because they establish the architecture from which later disease emerges. IgH translocations and hyperdiploidy are identified as the major primary cytogenetic events, and each produces biologically distinct founding clones. These lesions do more than mark diagnosis; they constrain the route of future progression.
IgH translocations can place oncogenic control under the influence of immunoglobulin regulatory elements, while hyperdiploidy creates a different founding state built on chromosome gain. Those two starting points do not simply coexist as labels. They shape downstream evolutionary trajectories, influence which secondary lesions appear most efficiently, and help determine the tempo of progression. The biology is evolutionary in the strict sense: once a founding clone is established, later adaptation must work within the limits of that initial genomic scaffold.
Secondary lesions drive progression, plasticity, and treatment resistance
Disease progression in multiple myeloma is increasingly linked to a recognizable set of secondary genomic changes. Copy number alterations, MYC activation, TP53 loss, and structural rearrangements contribute to genomic instability and transcriptional plasticity. These lesions do not act as isolated markers. They interact, accumulate, and intensify the malignant phenotype.
TP53 loss is especially important because it removes a major genomic safeguard and allows damaged clones to survive despite ongoing stress. MYC activation pushes proliferation and can widen the transcriptional programs available to the tumor. Structural rearrangements add another layer of instability, enabling a disease state that can adapt to changing selective forces, including exposure to therapy. In clinical terms, the result is a malignancy that is biologically capable of changing course while treatment is underway.
The progression pathway is therefore not linear. It is branched, dynamic, and repeatedly edited by selection.
Longitudinal clonal evolution explains why one relapse rarely resembles the last
Longitudinal studies reveal branching clonal architectures shaped by treatment-driven selection. That observation has direct biological implications. If multiple related subclones are present, a therapy may suppress the dominant population while leaving behind a resistant branch that later expands. Relapse then reflects not simple failure of a drug, but selection of a pre-existing or newly advantaged subclone.
This evolutionary framework helps explain why serial monitoring matters in a disease like multiple myeloma. A snapshot at diagnosis may capture the dominant clone, but it cannot fully describe the subclonal diversity that will later determine resistance patterns. As treatment pressure changes, the clonal hierarchy can shift. Some lesions may become more relevant over time, while others fade into the background. The tumor behaves less like a static mass and more like a population under continual ecological stress.
Genomic biomarkers may support adaptive treatment planning, but the field is not there yet
The clinical promise of this framework lies in combining germline and somatic information to refine risk stratification and anticipate high-risk trajectories. In principle, such integration could help identify patients more likely to follow aggressive evolutionary paths, and it could support more adaptive treatment strategies aimed at deeper and more durable disease control.
Still, the article stays appropriately restrained on clinical implementation. The framework is clinically oriented, but it does not claim that germline testing or polygenic risk scoring is ready to guide routine screening decisions. The most immediate utility remains conceptual and translational: a better map of how inherited susceptibility, founding cytogenetics, and later genomic instability connect across the disease course.
That separation matters in practice. A biologic model can be compelling long before it becomes actionable at the bedside.
A precision approach in myeloma will have to follow the disease over time
The central message is not simply that multiple myeloma is genetically complex. It is that its complexity unfolds over time, and each stage of the disease can alter the meaning of the next. Germline susceptibility may predispose to precursor states. Primary cytogenetic events may determine the founding route. Secondary abnormalities may then intensify instability and resistance. Treatment adds a final layer by selecting the clones best equipped to survive.
A precision framework built on that sequence would need longitudinal sampling, attention to clonal architecture, and caution about overpromising what current risk tools can deliver. For now, polygenic risk scores remain research instruments, not screening tools. The strongest near-term value of this work lies in clarifying how inherited and acquired lesions should be interpreted together rather than in isolation.
What emerges is a disease model built on evolution, not endpoint thinking. In multiple myeloma, the clinically relevant genome is the one still changing.